uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

uniQure N.V.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on uniQure (QURE) and Sandoz Group Ltd (SDZXF) with bul...

Analysts Are Bullish on Top Healthcare Stocks: uniQure (QURE), Sandoz Group Ltd (SDZXF)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Jazz Pharmaceuticals (JAZZ), uniQure (QURE) and Su...

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), uniQure (QURE) and Surgery Partners (SGRY)

Chardan Capital analyst Daniil Gataulin reiterated a Buy rating on uniQure yesterday and set a price target of $37.00. According to TipRanks, Gatau...

Chardan Capital Remains a Buy on uniQure (QURE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE) and uniQure (QURE) with bu...

Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), uniQure (QURE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rhythm Pharmaceuticals (RYTM), LeonaBio (LONA) and u...

Analysts’ Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), LeonaBio (LONA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on NovoCure (NVCR), Verano Holdings (VRNO) and uniQure ...

Analysts Are Bullish on These Healthcare Stocks: NovoCure (NVCR), Verano Holdings (VRNO)

U.S. chess champion Hikaru Nakamura continues to beat the S&P 500, with QURE, APP and ABVX having the most upside in his TipRanks Investment Portfo...

Market Cap	$1.56B	P/E Ratio	N/A
52W High	$71.50	52W Low	$8.73
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-8.5%	52W Position	26.2%
Overall Score	44	Value Score	40
Quality Score	44	Technical Score	50

EPS Current Est	$-3.68	EPS Next Est	$-3.43
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	QURE	$25.15	+3.97%	1.22M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	QURE	$25.15	+4.0%	1.22M
3
4
5
6

QURE

QURE

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get uniQure N.V. Data in Excel

Get uniQure N.V. Data in Excel